Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

SAN DIEGO and BEIJING, Jan. 13, 2020 /PRNewswire/ --A Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of next generation biologics using an expanded genetic code and Sino Biopharmaceutical Limited (1177.HK), a leading Chinese pharmaceutical company with a large number of A medical products covering multiple therapeutic areas, announced a joint collaboration to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms.
Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics
Under the agreement, Ambrx received an upfront payment to create two innovative drug candidates, with Sino Biopharma then leading IND enabling activities for both China and the US. The parties will jointly develop the programs to world-class standards with Sino Biopharma commercializing the products within the greater China area and Ambrx commercializing the products rest-of-world. Ambrx is eligible to receive additional milestone payments for development, regulatory, and sales-based events, as well as tiered royalties on future sales.A "We are delighted to join forces with Ambrx, a leader in precision engineered biologics and breakthrough protein therapeutics, to develop two next generation cancer drugs," commented Stephen Hsin Tse, Executive Director of Sino Biopharma. "This collaboration helps fulfill our strong commitment to develop and commercialize innovative biological drugs for the China market."The collaboration combines Ambrx's clinically validated ReCODEa?? and EuCODEa?? platforms with Sino Biopharma's strong resources and commitment to bring next-generation biologic drugs to market.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »